The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, U.S. September 17, 2020. Picture taken September 17, 2020. Brendan McDermid
The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, U.S. September 17, 2020. Picture taken September 17, 2020. Brendan McDermid

Regeneron beats quarterly estimates on eczema drug strength, shares rise

July 30th, 2026 | 11:54 AM BUSINESS Healthcare & Pharmaceuticals 1

Facebook Twitter Google+ LinkedIn Pinterest
By Reuters

Regeneron (REGN.O) on Thursday beat Wall Street estimates for second-quarter revenue and profit, helped by ​strong demand for its eczema drug Dupixent and ‌a high-dose version of its eye drug Eylea.

Shares rose nearly 5% before the bell.

Here are the details:

Related Posts

© Financetime.org 2026. All rights reserved. Hosted by LeadsDeposit.com
Produced by C-iT